Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction.

Alzheimer's disease (AD) is the most common cause of dementia worldwide. Because Alzheimer's disease has no known treatment, sufferers and their caregivers must concentrate on symptom management. Astrocytes and microglia are now known to play distinct physiological roles in synaptic function, the blood-brain barrier, and neurovascular coupling. Consequently, the search for drugs that can slow the degenerative process in dementia sufferers continues because existing drugs are designed to alleviate the symptoms of Alzheimer's disease. Drugs that address pathological changes without interfering with the normal function of glia, such as eliminating amyloid-beta deposits, are prospective treatments for neuroinflammatory illnesses. Because neuron-astrocytes-microglia interactions are so complex, developing effective, preventive, and therapeutic medications for AD will necessitate novel methodologies and strategic targets. This review focused on existing medications used in treating AD amongst which include Donepezil, Choline Alphoscerate, Galantamine, Dextromethorphan, palmitoylethanolamide, citalopram, resveratrol, and solanezumab. This review summarizes the effects of these drugs on neurons, astrocytes, and microglia interactions based on their pharmacokinetic properties, mechanism of action, dosing, and clinical presentations.

COVID-19 outcomes in HIV patients: A review.

The effect of COVID-19 is enormous, and high-risk COVID-19 case arises when underlying infections like diabetes, chronic obstructive pulmonary disease, heart failure, coronary artery disease, or cardiomyopathy are present, and an immunocompromised state such as Human Immunodeficiency Virus (HIV). People living with HIV(PLHIV) may be exposed to severe COVID-19, mostly in areas with poor access to proper care and complex intervention for HIV infection. During the lockdown, those with medical appointments will not access health facilities, which may be detrimental to people living with HIV. Emerging evidence suggests COVID-19 pandemic fear may lead to adverse mental health outcomes and affect preventive behavior. In addition to the stigma and discrimination associated with HIV, COVID-19 is also causing concerns. People with HIV tend to have mental health issues such as depression, anxiety, and post-traumatic stress (PTSD), which can be both a cause and a harmful impact of HIV. Discussed in this research is the effect of the COVID-19 pandemic on HIV patients, their similarities, differences, and urgent attention from healthcare centers to take charge and respond to patients with HIV and other immunosuppressed conditions during the COVID-19 pandemic.

The understanding of Parkinson's disease through genetics and new therapies.

INTRODUCTION: Parkinson's disease is one of the progressive neurodegenerative diseases from which people suffer for years. The mechanism of this disease is associated with a decrease in the number of dopaminergic neurons in the substantia nigra (SN) while Lewy bodies are still present. As a result, both motor-ridity, tremor, and bradykinesia-and non-motor symptoms such as anxiety and depression. Nowadays, it is well known that the cause behind Parkinson's disease is mainly environmental changes, genetic susceptibility, and toxins. Unfortunately, there is no cure for the disease but treatments. The replacement of lost neurons, α-synuclein and apomorphine, is currently being studied for new therapies. This article focuses on history, mechanism, factors causing Parkinson's disease as well as future therapies for the cure of the diseases. METHODOLOGY: Data were collected from medical journals published on PubMed, The Lancet, Cells, and Nature Reviews Neurology databases with a predefined search strategy. All articles considering new therapies for Parkinson's disease were considered. RESULTS: The pathophysiology of Parkinson's disease is currently reasonably understood. However, there is no definitive cure so all the treatments focus mainly on reducing or limiting the symptoms. Current treatment studies focus on genetics, replacing lost neurons, α-synuclein and apomorphine. CONCLUSION: Parkinson's disease is the most common movement disorder worldwide because of the loss of dopaminergic neurons in the substantia nigra. Its symptoms include motor dysfunctions such as rigidity, tremor, and bradykinesia and non-motor dysfunctions such as anxiety and depression. Through genetics, environmental changes and toxins analysis, it is now known that future new therapies are working on replacing lost neurons, α-synuclein and apomorphine.